Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Actuate Therapeutics Inc (ACTU)

Actuate Therapeutics Inc (ACTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib in Combination with GnP for Metastatic Pancreatic Cancer Quiver Quantitative, Inc. - Tue Dec 17, 5:40PM CST

Actuate Therapeutics reports significant survival improvements in pancreatic cancer patients treated with elraglusib and GnP, with ongoing trials.Quiver AI SummaryActuate Therapeutics, Inc. announced promising...

ACTU : 6.77 (-3.97%)
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer GlobeNewswire - Tue Dec 17, 7:28AM CST

ACTU : 6.77 (-3.97%)
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer GlobeNewswire - Tue Dec 17, 7:00AM CST

ACTU : 6.77 (-3.97%)
Actuate Therapeutics to be Added to Russell 2000® Index GlobeNewswire - Tue Nov 26, 7:00AM CST

ACTU : 6.77 (-3.97%)
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma GlobeNewswire - Tue Nov 12, 7:00AM CST

ACTU : 6.77 (-3.97%)
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development GlobeNewswire - Tue Oct 29, 5:39PM CDT

ACTU : 6.77 (-3.97%)
Alta Copper Announces Annual General Meeting Voting Results ACCESSWIRE - Sun Jun 30, 8:15AM CDT

VANCOUVER, BC / ACCESSWIRE / June 30, 2024 / Alta Copper Corp. (TSX:ATCU)(OTCQX:ATCUF)(BVL:ATCU) ("Alta Copper" or "the Company") announces voting results for its Annual General Meeting of shareholders...

ACTU : 6.77 (-3.97%)
ATCU.TO : 0.4450 (+4.71%)
ATCUF : 0.2890 (-10.80%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot